Ingenium's INGENOtyping(TM) technology is based on a genetically subtle chemical process that generates point mutations in genes and Ingenium's expertise in quickly and reliably producing and analyzing mammalian models of disease. The basis of Ingenium's business is its knowledge and expertise in generating the biological information critical to the discovery, validation and development of therapeutics.

Ingenium's drug discovery technologies combine functional genetics in the rodent model system with proprietary, therapeutic goal-oriented biological screens and advanced biological pathway analysis. From the breadth of knowledge generated by the company's Deductive Genomics(R) technology, Ingenium is currently advancing a portfolio of validated therapeutic concepts in the areas of inflammation, obesity/diabetes, and neurobiology.

The company's INGENOtyping(TM) platform offers the most rapid access to innovative rat and mouse models for drug discovery and development and drug target validation. Ingenium has corporate agreements with multiple companies, including Bayer AG, Elan Corporation, F. Hoffmann-La Roche Ltd. and Wyeth, in addition to numerous international academic collaborations.